SheMed, London’s female-founded HealthTech firm altering how girls entry personalised healthcare, immediately introduced it has raised €43 million to additional develop its progressive well being platform and advance new breakthroughs for preemptive healthcare.
The brand new funding will probably be used to broaden SheMed’s UK operations, scaling its medical and know-how groups, strengthening scientific infrastructure and enhancing its data-driven capabilities.
“For greater than a decade, I looked for solutions to an undiagnosed well being challenge,” stated Olivia Ferro, Co-founder and CEO of SheMed. “As a GLP-1 affected person myself, I understand how transformative the appropriate analysis and therapy might be. We constructed SheMed to offer girls the personalised help I struggled to seek out: care that listens, understands and empowers.”
The brand new funding for SheMed matches inside a broader wave of 2025 funding exercise in UK and European HealthTech, notably in preventative care and girls’s well being.
Different UK corporations in adjoining areas have additionally attracted important capital this 12 months – together with Numan, which secured €51.6 million to broaden its digital healthcare platform into feminine well being, and Hormona, which raised €7.8 million for its AI-driven hormone well being monitoring resolution.
Associated UK-based ventures reminiscent of Perci Well being and CoMind have additionally secured recent capital to advance personalised and data-led healthcare options.
In line with EU-Startups’ evaluation, UK startups collectively raised round €14.7 billion in 2025 thus far, signalling sustained investor confidence within the nation’s innovation ecosystem.
Inside this context, SheMed’s new funding displays each a robust nationwide momentum and the rising investor recognition of girls’s well being and metabolic-care platforms as key development areas in European healthcare innovation.
“The demand for SheMed’s providers has been extraordinary,” added Chloe Ferro, Co-founder and President of SheMed. “Ladies are searching for care that recognises their individuality, their biology and their experiences. It’s why girls proceed to show to SheMed for a tailor-made, extra supportive path to healthcare.”
Based in April 2024 by sisters Olivia and Chloe Ferro, SheMed has grown quickly to a market frontrunner for its potential to handle the persistent hole in girls’s healthcare: entry to customised, reliable and sustainable options.
Its programme integrates medical oversight, wellness monitoring and 24/7 help by way of an all-in-one digital platform, making certain each lady receives tailor-made particular person care whereas offering a platform that’s redefining the healthcare house.
The brand new funding may even help new analysis and patient-experience initiatives designed to enhance entry to high-quality, personalised care for girls throughout the UK.
SheMed is most recognized for its main GLP-1 and weight-management platform, which blends medical experience, knowledge insights and steady help to assist girls obtain lasting well being outcomes.
In lower than a 12 months, SheMed has cared for 60k+ members, reportedly cementing its place because the quickest rising GLP-1 programme within the UK.
Later this month, SheMed will publish outcomes from the first-ever female-focused GLP-1 scientific research, marking a big milestone in girls’s metabolic-health analysis. The findings will present insights into how GLP-1 drugs have an effect on girls’s hormonal and metabolic responses, serving to refine future therapy pathways.
